Nano Mobile Healthcare

Nano Mobile Healthcare FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Nano Mobile Healthcare (VNTH) as of Nov 5, 2026 is -153.33 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 34.64 % — a change of -542.70% (lower).

FCF Conversion

-153.33 %

YoY

-542.70%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Nano Mobile Healthcare is 2022 -153.33 % . FCF Conversion Rate (FCF/EBITDA) of Nano Mobile Healthcare was 2021 34.64 % . It decreases by -542.70% lower compared to the previous year.

The Nano Mobile Healthcare FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
22.55 USD
Jan 1, 2015
-111.46 USD
Jan 1, 2016
34.64 USD
Jan 1, 2022
-153.33 USD
The Nano Mobile Healthcare FCF Conversion history
YEARFCF ConversionYoY
-153.33 %-542.70%
34.64 %-131.07%
-111.46 %-594.36%
22.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nano Mobile Healthcare Stock analysis

What does Nano Mobile Healthcare do? Nano Mobile Healthcare, Inc. generates revenue through the development and sale of detection devices based on patented NASA technology. The company licenses its products from Nanobeak, which holds the original NASA patent, and focuses on disease screening and drug detection applications. Its primary customers are healthcare providers and pharmaceutical companies seeking advanced diagnostic tools. The firm's products integrate nano-electronics, bio-informatics, and wireless technology to deliver innovative screening solutions. The company's business model relies on licensing agreements with Nanobeak for the NASA-developed technology, which is then adapted for medical use. By leveraging this patented technology, Nano Mobile Healthcare targets healthcare institutions and pharmaceutical firms requiring precise diagnostic capabilities. The firm's product line centers on disease and drug screening, positioning it within the medical device sector without specifying additional market segments. Revenue streams are derived from the sale of detection devices and related services, with no mention of subscription models or additional product lines. The company's focus remains on the convergence of nano-electronics, bio-informatics, and wireless technology for medical applications, ensuring alignment with its core technological foundation. Nano Mobile Healthcare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nano Mobile Healthcare stock

FCF Conversion Rate (FCF/EBITDA) of Nano Mobile Healthcare is -153.33 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of Nano Mobile Healthcare changed from 34.64 % to -153.33 %, representing a -542.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Nano Mobile Healthcare since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Nano Mobile Healthcare with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nano Mobile Healthcare

All Key Metrics — Nano Mobile Healthcare